NCT06667128View on ClinicalTrials.gov

Optimization of Heart Failure (HF) Medical Therapy After Transcatheter Valve Intervention (TVI) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)

NANot yet recruitingINTERVENTIONAL
Enrollment

160

Participants

Timeline

Start Date

February 1, 2025

Primary Completion Date

February 1, 2026

Study Completion Date

February 1, 2026

Conditions
Heart FailureValvulopathyAortic StenosisAortic Regurgitation DiseaseMitral RegurgitationTricuspid RegurgitationBrain Natriuretic PeptideMitraclipTAVI(Transcatheter Aortic Valve Implantation)
Interventions
OTHER

Rapid Uptitration of Guideline-Directed Medical Therapy

Rapid up-titration of GDMT guided by protocol-specific guideline.

DIAGNOSTIC_TEST

Elecsys® NT-proBNP - Roche Diagnostics

An assay provided by Roche (Elecsys® NT-proBNP - Roche Diagnostics) will be used to assess NT-proBNP levels in the Rapid Up-Titration GDMT Group with Point-of-Care (PoC) Monitoring, with the purpose of evaluating any differences in marker dosage between the indicated method and the monitoring by the hospital laboratory analysis.

OTHER

Rapid Up-Titration GDMT Group with Hospital Monitoring

Rapid Up-Titration GDMT Group guided by protocol-specific guideline and hospital monitoring.

Trial Locations (1)

20132

IRCCS Ospedale San Raffaele, Milan

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

IRCCS Ospedale San Raffaele

OTHER

NCT06667128 - Optimization of Heart Failure (HF) Medical Therapy After Transcatheter Valve Intervention (TVI) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF) | Biotech Hunter | Biotech Hunter